DAVID H. SPODICK, M.D., D.SC.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In their well-written editorial note in the February issue, Engel and Meister (1) raise appropriate caveats about the mixed blessings and potential dangers of the promising new mechanical procedure for coronary artery disease, transluminal balloon angioplasty. They also appropriately note its successes but include a well-reasoned caution. This was a needed analysis, yet it was profoundly disappointing not to find any reference to the need for appropriately designed controlled clinical trials with random allocation of comparable patients.
If we are to compare this with any other treatment or with no treatment, trial-and-error is no longer acceptable. Surely,
SPODICK DH. Percutaneous Transluminal Coronary Angioplasty. Ann Intern Med. ;90:850–851. doi: 10.7326/0003-4819-90-5-850
Download citation file:
Published: Ann Intern Med. 1979;90(5):850-851.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use